Yahoo Finance Aquestive Therapeutics, Inc. (NASDAQ:AQST) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Last week, you might have seen that Aquestive Therapeutics, Inc. (NASDAQ:AQST) released its first-quarter result to the market. The early response was not positive, with shares down 5.9% to US$3.09 in the past week. Revenues were in line with expectations, at US$12m, while statutory losses ballooned to US$0.17 per share. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Aquestive Therapeutics after the latest results.
See our latest analysis for Aquestive Therapeutics
Taking into account the latest results, the seven analysts covering Aquestive Therapeutics provided consensus estimates of US$49.8m revenue in 2024, which would reflect a measurable 3.4% decline over the past 12 months. Per-share losses are predicted to creep up to US$0.34. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$50.1m and losses of US$0.37 per share in 2024. It looks like there's been a modest increase in sentiment in the recent updates, with the analysts becoming a bit more optimistic in their predictions for losses per share, even though the revenue numbers were unchanged.
There's been no major changes to the consensus price target of US$8.88, suggesting that reduced loss estimates are not enough to have a long-term positive impact on the stock's valuation. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. There are some variant perceptions on Aquestive Therapeutics, with the most bullish analyst valuing it at US$13.00 and the most bearish at US$7.00 per share. Note the wide gap in analyst price targets? This implies to us that there is a fairly broad range of possible scenarios for the underlying business.
Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. One more thing stood out to us about these estimates, and it's the idea that Aquestive Therapeutics' decline is expected to accelerate, with revenues forecast to fall at an annualised rate of 4.5% to the end of 2024. This tops off a historical decline of 2.4% a year over the past five years. Compare this against analyst estimates for companies in the broader industry, which suggest that revenues (in aggregate) are expected to grow 9.3% annually. So it's pretty clear that, while it does have declining revenues, the analysts also expect Aquestive Therapeutics to suffer worse than the wider industry.
The Bottom Line
The most important thing to take away is that the analysts reconfirmed their loss per share estimates for next year. Fortunately, the analysts also reconfirmed their revenue estimates, suggesting that it's tracking in line with expectations. Although our data does suggest that Aquestive Therapeutics' revenue is expected to perform worse than the wider industry. The consensus price target held steady at US$8.88, with the latest estimates not enough to have an impact on their price targets.
Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. At Simply Wall St, we have a full range of analyst estimates for Aquestive Therapeutics going out to 2026, and you can see them free on our platform here..
Before you take the next step you should know about the 3 warning signs for Aquestive Therapeutics (2 are potentially serious!) that we have uncovered.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
